Twist Bioscience Co. (NASDAQ:TWST) Receives $51.90 Consensus Target Price from Analysts

Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the ten brokerages that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and eight have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $51.90.

Several equities analysts have commented on TWST shares. Robert W. Baird increased their price objective on shares of Twist Bioscience from $46.00 to $48.00 and gave the company an "outperform" rating in a research report on Tuesday, November 19th. TD Cowen restated a "buy" rating and set a $58.00 target price on shares of Twist Bioscience in a research report on Tuesday, November 26th. Wolfe Research assumed coverage on Twist Bioscience in a research report on Friday. They issued an "outperform" rating and a $60.00 price target for the company. Barclays decreased their price objective on Twist Bioscience from $55.00 to $52.00 and set an "overweight" rating on the stock in a research report on Tuesday, November 19th. Finally, Scotiabank raised their price objective on Twist Bioscience from $50.00 to $54.00 and gave the company a "sector outperform" rating in a research note on Tuesday, November 19th.

Twist Bioscience Stock Performance

Shares of TWST traded up $0.11 during mid-day trading on Friday, hitting $47.50. 814,078 shares of the stock were exchanged, compared to its average volume of 940,837. The firm has a 50-day moving average of $44.94 and a two-hundred day moving average of $46.66. Twist Bioscience has a 52-week low of $27.41 and a 52-week high of $60.90. The company has a market cap of $2.82 billion, a PE ratio of -13.19 and a beta of 1.82.

Insider Buying and Selling

In other news, CFO Adam Laponis sold 856 shares of the firm's stock in a transaction that occurred on Wednesday, October 9th. The shares were sold at an average price of $41.81, for a total transaction of $35,789.36. Following the transaction, the chief financial officer now directly owns 73,397 shares of the company's stock, valued at approximately $3,068,728.57. This trade represents a 1.15 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CAO Robert F. Werner sold 1,448 shares of the business's stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $44.60, for a total value of $64,580.80. Following the completion of the sale, the chief accounting officer now owns 45,620 shares of the company's stock, valued at $2,034,652. The trade was a 3.08 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 101,787 shares of company stock valued at $4,584,508. Insiders own 3.92% of the company's stock.

Hedge Funds Weigh In On Twist Bioscience

A number of hedge funds and other institutional investors have recently made changes to their positions in TWST. Wilmington Savings Fund Society FSB bought a new position in shares of Twist Bioscience during the third quarter valued at approximately $34,000. Signaturefd LLC boosted its position in Twist Bioscience by 63.0% during the 3rd quarter. Signaturefd LLC now owns 792 shares of the company's stock valued at $36,000 after acquiring an additional 306 shares in the last quarter. EdgeRock Capital LLC purchased a new position in shares of Twist Bioscience in the 2nd quarter valued at $43,000. Blue Trust Inc. increased its holdings in shares of Twist Bioscience by 2,912.8% in the 2nd quarter. Blue Trust Inc. now owns 1,175 shares of the company's stock valued at $58,000 after acquiring an additional 1,136 shares during the period. Finally, DekaBank Deutsche Girozentrale bought a new position in shares of Twist Bioscience in the 2nd quarter worth $61,000.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.